CSF1R and hepatocellular carcinoma: The heterogeneity of the HCC TME, dynamic TAM plasticity, and compensatory mechanisms hinder the success of TAM-targeting therapies, as evidenced by the disappointing results of CSF-1R inhibitor combinations with ICIs in clinical trials.